Peter Maslak, MD, is an expert Hematologic Oncologist, joining Roswell Park as Vice Chair of Clinical Affairs, Director of Flow Cytometry in the Immune Monitoring Shared Resource and the Technical Director of the Flow Cytometry Lab.
Roswell Park Comprehensive Cancer Center pre-doctoral trainee Payal Goala, MS, BS, presented research findings that hold potential to help address two significant toxicities associated with Chimeric Antigen Receptor (CAR) T-cell therapy.
A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein called GPRC5D antigen produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Memorial Sloan ...
Following a national search, Roswell Park Comprehensive Cancer Center has appointed Marco Davila, MD, PhD, as Senior Vice President and Associate Director for Translational Research and Vice-Chair for Cellular Therapies.
Roswell Park is spearheading efforts to study innovative CAR T-cell therapies in addition to offering traditional treatment approaches.
Three physician-scientists who have relocated to Buffalo, New York, to join Roswell Park Comprehensive Cancer Center will apply highly specialized transplantation and cell therapy (TCT) expertise to both patient care and the development ...
Several factors contribute to improving the success and safety of allogeneic stem cell transplant. At Roswell Park, we deploy three key strategies to help our patients achieve better outcomes and quality of life.
A promising cancer innovation developed at Roswell Park Comprehensive Cancer Center has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA).
This site is intended for healthcare professionals